Avandaryl Tablets

(contact us for more information on Avandaryl Tablets)
Brand NameAvandaryl Tablets
Generic Namerosiglitazone maleate and glimepiride
Marketed byGlaxoSmithKline PLC
NDA/BLA HolderSB Pharmco
NDA/BLA NumberNDA 21-700/S-008
NDA/BLA Approval Date11/23/2005
StatusApproved
Review ClassificationStandard
REMS Approval Date12/2/2008
Class REMSNo
REMS Source Document
Boxed Warning?
Boxed Warning
Indication
Route of Administration
Mechanism of Action
Risks
Risks (MedGuide Language)
Approved Labeling
Medication Guide?
Medication Guide
Medication Guide Version
Communication Plan?
Communication Plan
Elements to Assure Safe Use?
Elements to Assure Safe Use
Implementation System?
Implementation System
Assessment Program
Assessment Program Timeline
Branded Program
Program Description
Link to Branded Program
Deemed/Approved
Approval Letters

Sources

REMS Document: from FDA Approved REMS
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm

Approval Letters: from FDA Medication Guide Website
(http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Search_Drug_Name)

Approved Labeling: from FDA Medication Guide Website
(http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Search_Drug_Name)

Medication Guide: from FDA Medication Guide Website
(http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Search_Drug_Name)

Previous page: REMS Directory Next page: REMS White Papers
 
Register for periodic industry updates:

2013-2014© 2013 ParagonRx. All rights reserved.